ADC Therapeutics SA (ADCT)

4,4100 -0,0300 (-0,68%) A partir del 02:21PM EDT. Mercado abierto.

ADC Therapeutics SA

Biopôle
Route de la Corniche 3B
Epalinges 1066
Switzerland
41 21 653 02 00
https://www.adctherapeutics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 273

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Ameet Mallik M.B.A., M.S.	CEO & Director	1,84M	N/A	1973
Mr. Jose I. Carmona M.B.A.	Chief Financial Officer	884,86k	N/A	1972
Dr. Mohamed Zaki M.D., Ph.D.	Chief Medical Officer	2,41M	N/A	1965
Ms. Lisa Michelle Kallebo	Corporate Controller & Chief Accounting Officer	N/A	N/A	N/A
Dr. Michael Mulkerrin Ph.D.	Chief Technical Operations Officer	N/A	N/A	1955
Dr. Patrick van Berkel Ph.D.	Chief Scientific Officer	N/A	N/A	1968
Amanda Hamilton	Investor Relations Officer	N/A	N/A	N/A
Mr. Peter J. Graham Esq.	Chief Legal Officer	N/A	N/A	1967
Ms. Eugenia Litz	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Kimberly Pope	Senior VP & Chief People Officer	N/A	N/A	1967

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Gobierno corporativo

El ISS Governance QualityScore de ADC Therapeutics SA, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.